AVANIR Pharmaceuticals | Evaluate

Neurocrine picks Takeda’s brain

Neurocrine Biosciences' latest collaboration, with Takeda, gives it three more high-risk bets in neuroscience.

Axsome advances in agitation, but confirmatory study is still needed

January 08, 2015

Buoyant small pharma market hides some big losers

December 02, 2014

Otsuka price should have Avanir investors laughing all the way to the bank

October 06, 2014

Acquisitions help define performance of mid and small cap stocks

September 16, 2014

Avanir’s Alzheimer’s data prompt unchecked outburst of investor enthusiasm

October 25, 2013

Therapeutic focus – Treating dyskinesia proves as elusive as Parkinson’s itself

December 24, 2012

Midcap players ask Europe to bring it on in 2013

May 11, 2012

First quarter data reveal new drug launches remain challenging

January 06, 2012

Investors buoyed by signs of speedier drug launches

September 19, 2011

Transcept and Vivus hoping to buck the trend with another approval chance

Load More